Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

 Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

Shots:

  • The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment
  • The P-II study met its 1EP of prolonged PFS, safety is consistent with previously published data on the individual components of the combination, no new safety signals were identified
  • Aliqopa is a PI3K inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells and is an approved treatment for patients with relapsed FL prior treated with two systemic therapies

    Click here to­ read the full press release/ article | Ref: Businesswire Image: Business Insider

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post